Literature DB >> 30607020

Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.

Maria Gounari1,2, Stavroula Ntoufa1, Marta Muzio2, Kostas Stamatopoulos3,4, Paolo Ghia2, Marina Gerousi1, Maria Giovanna Vilia2, Theodoros Moysiadis1, Konstantia Kotta1, Nikos Papakonstantinou1, Lydia Scarfò2, Andreas Agathangelidis1, Eleonora Fonte2, Pamela Ranghetti2, Athanasia Nenou1, Aliki Xochelli1, Marta Coscia5, Alessandra Tedeschi6, Niki Stavroyianni7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30607020     DOI： 10.1038/s41375-018-0335-2

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Authors:  Kallesh D Jayappa; Craig A Portell; Vicki L Gordon; Brian J Capaldo; Stefan Bekiranov; Mark J Axelrod; L Kyle Brett; Julia D Wulfkuhle; Rosa I Gallagher; Emanuel F Petricoin; Timothy P Bender; Michael E Williams; Michael J Weber
Journal:  Blood Adv       Date:  2017-06-13

Review 2.  Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.

Authors:  C Brunner; B Müller; T Wirth
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.